The DPMCDA Medications Discovery & Toxicology Branch plans, designs, implements, and coordinates
a set of comprehensive pre-clinical discovery programs with the goal of identifying potential
medications to treat the most common abused illegal drugs such as
cocaine, methamphetamine, marijuana, nicotine, and opiates. Within the discovery programs, the
primary activities of the Medications Discovery & Toxicology Branch include in vitro
receptor and transporter activity screening; pre-clinical behavioral screening; and
pharmacological profiling of candidate medications. The Branch is working to identify
new molecular entities and to manage information on drug discovery targets. The Drug
Discovery and Development System helps researchers acquire, track, analyze, and manage
data throughout a compound's lifecycle. These data are used to identify potential
compounds to recommend for advancement to NIDA's drug development pipeline.
The Drug Discovery and Development System (Discovery Application)
The Discovery application gives NIDA the ability to record, monitor and track the progress
of a compound and compare the completed laboratory results to other compounds across and
within the addiction treatment discovery program.
The application generates authorization forms and letter templates that are used by NIDA
to send and receive compound information to compound submitters and laboratory
testing sites. The Discovery application displays summary and detailed compound
testing data conducted by and received from the laboratories. These results aid in the
compound advancement decision making process to assess a compound's potential
as an alternative substitute or treatment for persons with drug dependency.
For more details, contact Discovery Support at
NIDA_Discovery@imc.com.
|
|
|
